Sick before old

Britain has a healthspan crisis. The country is increasingly sick years before it is old, and the late expression of a single underlying biology is the underlying biology.

The statistics are stark. Sixty point seven percent of UK adults aged forty-five to sixty-four are living with two or more long-term conditions. Two point eight million UK adults are economically inactive due to long-term sickness. The cliff is steep, it begins in mid-life, and it is treated, in our healthcare framework, as something that arrives rather than something that is built.

The building begins decades earlier. Most chronic disease in the second half of life is the late expression of a single underlying biology, namely smouldering chronic inflammation, driven by metabolic dysfunction, deeply entangled with the gut microbiome. The biology is genuinely modifiable. The decades of energy, sharpness and capacity that should be the second half of life are not being delivered by a healthcare model that engages only when the late expression becomes clinically visible.

What follows is an outline of where policy could move if it were prepared to address the underlying biology directly. None of this is novel. The evidence base is in place. The clinical pathways exist. What is missing is the institutional alignment to deliver the work early, where the return is measured in decades.

The underlying biology is modifiable

What we eat, how we sleep, how we move. These are not soft levers. They are the root determinants of cardiovascular, metabolic, neurological and inflammatory trajectory across the decades. The published evidence on lifestyle modifiability is now extensive enough that the policy question is not whether the underlying biology can be changed but whether the healthcare framework is built to support that change at scale.

For most adults, the answer is no. The annual private health check market, where it exists, reassures rather than examines. The NHS framework engages when disease is clinically present, not when the biology that will produce it is shifting. The intermediate clinical work that addresses the underlying biology early sits in an institutional gap.

Where the work happens now

Specialised private clinical practice. The pre-launch EPOCH METABOLIC clinical work, and a handful of peers in the UK and US private healthcare market, are the institutional response so far. The pricing reflects the bespoke and longitudinal nature of the work; the market that can access it reflects the constraints of private healthcare delivery.

This is not sustainable as the only response to a population-level problem. The preventive work has to become accessible at scale, through structural arrangements that fund the public-good extension alongside the commercial offering. The EPOCH Foundation is one such arrangement in the UK private clinical space; other models are in development internationally.

The policy question

If chronic disease in the second half of life is the late expression of an underlying biology that is modifiable early, what is the public investment case for prevention-led clinical intervention in mid-life? The economic case is in front of us in the two point eight million number. The clinical case is in front of us in the published evidence. The institutional question is whether the framework can be built to deliver the work at scale.

This essay is the first in a series exploring that question across policy, clinical and societal dimensions. Subsequent essays will address the annual private health check market, the role of the microbiome biology, the cognitive sharpness dimension, and the institutional models that might deliver the work at scale.